Efficacy and tolerability of telmisartan plus amlodipine in added-risk hypertensive patients

References

• Ong KL, Cheung BM, Man YB, et al. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999–2004. Hypertension 2007;49:69-75
   PubMed Web of Science ®Google Scholar
• Schmieder RE, Ruilope LM. Blood pressure control in patients with comorbidities. J Clin Hypertens (Greenwich) 2008;10:624-631
   PubMed Web of Science ®Google Scholar
• Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289:2560-72
   PubMed Web of Science ®Google Scholar
• Mancia G, Laurent S, Agabiti-Rosei E, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009;27:2121-58
   PubMed Web of Science ®Google Scholar
• Banegas JR, Segura J, Ruilope L, et al. Blood pressure control and physician management of hypertension in hospital hypertension units in Spain. Hypertension 2004;43:1338-44
   PubMed Web of Science ®Google Scholar
• Dahlöf B. Management of cardiovascular risk with RAS inhibitor/CCB combination therapy. J Hum Hypertens 2009;23:77-85
   PubMed Web of Science ®Google Scholar
• Brachmann J, Ansari A, Mahla G, et al. Effective and safe reduction of blood pressure with the combination of amlodipine 5 mg and valsartan 160 mg in hypertensive patients not controlled by calcium channel blocker monotherapy. Adv Ther 2008;25:399-411
   PubMed Web of Science ®Google Scholar
• Smith TR, Philipp T, Vaisse B, et al. Amlodipine and valsartan combined and as monotherapy in stage 2, elderly, and black hypertensive patients: subgroup analyses of 2 randomized, placebo-controlled studies. J Clin Hypertens 2007;9:355-64
   PubMedGoogle Scholar
• Poldermans D, Glazes R, Kargiannis S, et al. Tolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertension. Clin Ther 2007;29:279-89
   PubMed Web of Science ®Google Scholar
• Chrysant SG, Melino M, Karki S, et al. The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study. Clin Ther 2008;30:587-604
   PubMed Web of Science ®Google Scholar
• Chrysant SG, Lee J, Melino M, et al. Efficacy and tolerability of amlodipine plus olmesartan medoxomil in patients with difficult-to-treat hypertension. J Hum Hypertens 2010;24:730-8
   PubMed Web of Science ®Google Scholar
• Philipp T, Smith TR, Glazer R, et al. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension. Clin Ther 2007;29:563-80
   PubMed Web of Science ®Google Scholar
• Littlejohn TW III, Majul CR, Olvera R, et al. Results of treatment with telmisartan–amlodipine in hypertensive patients. J Clin Hypertens (Greenwich) 2009a;11:207-13
   PubMed Web of Science ®Google Scholar
• Littlejohn TW III, Majul CR, Olvera R, et al. Telmisartan plus amlodipine in patients with moderate or severe hypertension: results from a subgroup analysis of a randomized, placebo-controlled, parallel-group, 4 × 4 factorial study. Postgrad Med 2009b;12:5-14
   Google Scholar
• Lacourcière Y, Krzesinski JM, White WB, et al. Sustained antihypertensive activity of telmisartan compared with valsartan. Blood Press Monit 2004;9:203-10
   PubMed Web of Science ®Google Scholar
• Smith DH, Cramer MJ, Neutel JM, et al. Comparison of telmisartan versus losartan: meta-analysis of titration-to-response studies. Blood Press Monit 2003;8:111-17
   PubMed Web of Science ®Google Scholar
• Yusuf S, Teo KK, Pogue J, et al. on behalf of the ONTARGET® Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358:1547-59
   PubMed Web of Science ®Google Scholar
• Williams B, Poulter NR, Brown MJ, et al. British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary. BMJ 2004;328:634-40
   PubMed Web of Science ®Google Scholar
• Stangier J, Schmid J, Türck D, et al. Absorption, metabolism, and excretion of intravenously and orally administered [14C]telmisartan in healthy volunteers. J Clin Pharmacol 2000;40(12 Pt 1):1312-22
   PubMed Web of Science ®Google Scholar
• Kurian AK, Cardarelli KM. Racial and ethnic differences in cardiovascular disease risk factors: a systematic review. Ethn Dis 2007;17:143-52
   PubMed Web of Science ®Google Scholar
• Ferdinand KC, Armani AM. The management of hypertension in African Americans. Crit Pathw Cardiol 2007;6:67−71
   Google Scholar
• Wright JT Jr, Dunn JK, Cutler JA, et al. Outcomes in hypertensive black and nonblack patients treated with chlothalidone, amlodipine, and lisinopril. JAMA 2005;293:1595-608
   PubMed Web of Science ®Google Scholar
• Sagnella GA. Why is plasma renin activity lower in populations of African origin? J Hum Hypertens 2001;15:17-25
   PubMed Web of Science ®Google Scholar
• The ACCORD Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010;362:1575-85
   PubMed Web of Science ®Google Scholar
• Denardo SJ, Messerli FH, Gaxiola E, et al. Coronary revascularization strategy and outcomes according to blood pressure (from the International Verapamil SR-Trandolapril Study [INVEST]). Am J Cardiol 2010;106:498-503
   PubMed Web of Science ®Google Scholar
• Sharma AM. Is there a rationale for angiotensin blockade in the management of obesity hypertension? Hypertension 2004;44:12-19
   PubMed Web of Science ®Google Scholar
• Cho S, Atwood JE. Peripheral edema. Am J Med 2002;113:580-6
   PubMed Web of Science ®Google Scholar